
Please try another search
On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharma (RARE) of his decision to retire from the Board of Directors of the Company (the “Board”), effective immediately after the Company’s 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023. Dr. Ekman’s decision to retire from the Board is for personal reasons and is not related to any disagreement with the Company or its management on the Company’s operation, policies, or practices.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.